AMENDMENT

In the claims:

Pursuant to 37 C.F.R. §1.121 the following is a complete listing of the claims of the present application. In this set of claims, please amend claims 11, 23, and 31 as indicated:

1. [Original] A compound selected from the group consisting of the formula:



where R^1 is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons; and

R^2 is an aliphatic chain having 10 to 18 carbons;

R^3 is a tertiary amine; and

R^4 is a group that is selectively hydrolyzed in a target cell.

2. [Original] The compound of claim 1 wherein R^3 is pyrrolidino.

---

3. [Currently Amended] The compound of claim 1 wherein R^4 is selected from the group consisting of an acetyl, $-CO(CH_2)nCH_3$ wherein n is at least 1 and



, wherein R^5 is an alkyl group.

---

4. [Original] The compound of claim 1 wherein R^1 is 4-hydroxyphenyl.

5. [Original] The compound of claim 1 wherein R^1 is 3,4-ethylenedioxy.

6. [Currently Amended] A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 1 ~~and~~ or pharmaceutically acceptable salts thereof.

7. [Currently Amended] A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 ~~and~~ or pharmaceutically acceptable salts thereof.

8. [Currently Amended] A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 ~~and~~ or pharmaceutically acceptable salts thereof.

9. [Currently Amended] A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 ~~and~~ or pharmaceutically acceptable salts thereof.

A2

10. [Currently Amended] A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 ~~and~~ or pharmaceutically acceptable salts thereof.

11. [Currently Amended] A vaccination method comprising the steps of:

a) ~~.~~ ~~removing~~ obtaining cancer cells sensitive to the compounds below from a patient;

b) ~~.~~ treating the cancer cells *in vitro* with an effective amount of a composition comprising the compound of claim 1 and pharmaceutically acceptable salts thereof.

12. [Original] A compound selected from the group consisting of the formula:



where R^1 is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons; and

R^2 is an aliphatic chain having 10 to 18 carbons;

R^3 is a tertiary amine; and

R^4 is a group that is selectively hydrolyzed in a target cell or a hydrogen; and

R^6 is a group that is selectively hydrolyzed in a target cell.

13. [Original] The compound of cl aim 12 wherein R^3 is pyrrolidino.

---

14. [Currently Amended] The compound of claim 12 wherein R^4 is selected from the group consisting of an acetyl, $-CO(CH_2)nCH_3$ wherein n is at least 1 and



, wherein R^5 is an alkyl group.

15 [Currently Amended] The compound of claim 12 wherein R^6 is selected from the group consisting of an acetyl, $-CO(CH_2)nCH_3$ wherein n is at least 1 and

A3



, wherein R^5 is an alkyl group.

---

16. [Original] The compound of cl aim 12 wherein R^1 is 4-hydroxyphenyl.

17. [Original] The compound of cl aim 12 wherein R^1 is 3,4-ethylenedioxy.

---

18. [Currently Amended] A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 12 ~~and~~ or pharmaceutically acceptable salts thereof.

19. [Currently Amended] A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 ~~and~~ or pharmaceutically acceptable salts thereof.

A4

20. [Currently Amended] A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 ~~and~~ or pharmaceutically acceptable salts thereof.

21. [Currently Amended] A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 ~~and~~ or pharmaceutically acceptable salts thereof.

22. [Currently Amended] A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 ~~and~~ or pharmaceutically acceptable salts thereof.

23. [Currently Amended] A vaccination method comprising the steps of:

a) ~~.~~ ~~removing~~ obtaining cancer cells sensitive to the compounds below from a patient;

b) ~~.~~ treating the cancer cells *in vitro* with an effective amount of a composition comprising the compound of claim 12 and pharmaceutically acceptable salts thereof.

---

24. [Original] A compound selected from the group consisting of the formulas:



or



where R^2 is an aliphatic chain having 10 to 18 carbons; and

R^3 is a tertiary amine.

25. [Original] The compound of cl aim 24 wherein R^3 is pyrrolidino.

---

26. [Currently Amended] A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 24 ~~and~~ or pharmaceutically acceptable salts thereof.

27. [Currently Amended] A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a

therapeutically effective amount of a composition comprising the compound of Claim 24 ~~and~~ or pharmaceutically acceptable salts thereof.

28. [Currently Amended] A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 ~~and~~ or pharmaceutically acceptable salts thereof.

29. [Currently Amended] A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 ~~and~~ or pharmaceutically acceptable salts thereof.

30. [Currently Amended] A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 ~~and~~ or pharmaceutically acceptable salts thereof.

31. [Currently Amended] A vaccination method comprising the steps of:

a) ~~removing~~ obtaining cancer cells sensitive to the compounds below from a patient;

b) treating the cancer cells *in vitro* with an effective amount of a composition comprising the compound of claim 24 and pharmaceutically acceptable salts thereof.